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Functional screening system 
for yeast-secreted peptides acting  
on G-protein coupled receptors
Tomohiro Shigemori, Kouichi Kuroda and Mitsuyoshi Ueda*
Abstract 
We established a novel functional screening system for peptides acting on G-protein coupled receptors (GPCRs). Pep-
tides are a promising drug scaffold because of their intermediate molecular size between that of therapeutic small 
molecules and antibodies. They also offer potential advantages of targeting not only membrane proteins but also 
intracellular protein–protein interactions. Phage display technology has been used for exploring novel peptides act-
ing on GPCRs, but it is unclear whether the identified peptides functionally modulate targets because the technol-
ogy selects peptides based on binding ability but not functional activity to targets. In a novel screening system that 
we established, yeast cells were utilized as a peptide producer while mammalian cells stably producing the receptor 
for glucagon-like peptide 1 (GLP1R) were used as a biosensor for receptor activation. Three kinds of GLP1R agonists 
secreted by yeasts were successfully detected for their functional activities without any purification and condensa-
tion of those peptides. By applying the functional screening system, we were able to identify GLP1R agonist-secreting 
yeasts based on GLP1R activation from the cell mixture containing a number of background yeasts that produced 
non-active control peptides. Further applications of this system would include not only activity evaluation of bioactive 
peptides without chemical synthesis but also discovery of novel peptides activating druggable GPCRs.
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Introduction
G-protein coupled receptors (GPCRs) are one of criti-
cal eukaryotic signal transduction gatekeepers and rep-
resent the largest protein family in the human proteome 
with more than 800 members. They share a common 
architecture of seven transmembrane helices, and can be 
classified into five major classes of sequence similarities 
(Jacoby et al. 2006): rhodopsin receptor family (class A), 
secretin-like receptor family (class B), glutamate recep-
tor family (class C), frizzled/taste 2 receptor family, and 
adhesion receptor family. GPCRs recognize a variety 
of extracellular stimuli, including photons, ions, small 
molecules, peptides, and proteins; they transmit the 
resulting extracellular signals across the membrane to 
elicit intracellular responses. Consequently, GPCRs are 
involved in physiological and pathophysiological changes 
in blood pressure, blood sugar, pain, allergies, and so on. 
Therefore, pharmacological activation or suppression of 
GPCRs has been effective means to treat various diseases 
related to GPCR dysregulation.
Peptides are involved in a variety of physiological and 
pathological processes, and play very important roles in 
modulating various cell functions such as the absorption 
of blood glucose into the body through the promotion 
of insulin secretion in pancreatic β-cells by glucagon-
like peptide-1 (GLP1), a peptide hormone that are post-
prandially secreted in intestinal L-cells and activates one 
of class B GPCRs, GLP1 receptor (GLP1R) (Baggio and 
Drucker 2007). Because of their intermediate molecular 
size ranging from 0.5 to 5 kDa which is between that of 
small-molecule drugs and therapeutic monoclonal anti-
bodies, peptides potentially have advantages of easy 
drug design, high safety, accessibility for protein–protein 
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interactions, targeting of intracellular molecules, and low 
production cost (Craik et al. 2013).
Phage display is the first innovative technology estab-
lished by Smith (1985) that allows researchers to pre-
pare and screen a large polypeptide library. However, 
this methodology is not effective at discovering func-
tional peptides such as activators for GPCRs. This is 
due to the nature of phage display, whose peptides are 
screened based only on binding ability to targets, result-
ing frequently in simple binding peptides without any 
bioactivity (Chen et  al. 2007). Furthermore, the identi-
fied peptides on the phage are never a functional, solu-
ble form, potentially leading to dissociation in activity 
between peptides tied up on the phage as a fusion protein 
and the secretion form of peptides.
The yeast Saccharomyces cerevisiae is suitable as host 
for production of peptide library; this is due to their 
abundance in gene manipulation tools, fast growth in 
a low-cost medium, and protein folding and secretory 
machinery homologous to that of mammalian cells (Idi-
ris et al. 2010). In this study, we report a novel functional 
screening method for bioactive peptides acting on GPCRs, 
which integrated a yeast secretion system and a functional 
detection system using GPCR-producing mammalian cells. 
GLP1R produced on mammalian cells was successfully 
activated by various GLP1R agonistic peptides that were 
secreted from yeast. We were also able to identify GLP1R 
agonist-secreting yeasts based on GLP1R activation from 
the cell mixture containing a number of background yeasts, 
which produced non-active control peptides, suggesting 
the effectiveness of our functional screening system to dis-
cover novel peptide-based drugs acting on GPCRs.
Materials and methods
Strains and media
Esherichia coli DH5α [F−, ΔlacU169 (ϕ80lacZΔM15), 
hsdR17 (rK−, mK+), recA1, endA1, deoR, thi-1, supE44, 
gyrA96, relA1, λ−] (Toyobo, Osaka, Japan) was used as a 
host for DNA manipulation. E. coli transformants were 
grown in Luria–Bertani (LB) medium [1% (w/v) tryptone, 
0.5% (w/v) yeast extract, 1% (w/v) sodium chloride, and 
2% (w/v) agarose] containing 100  µg/mL ampicillin or 
kanamycin depending on the plasmids introduced.
Saccharomyces cerevisiae BY4742 (MATα, his3Δ1, 
leu2Δ0, lys2Δ0, ura3Δ0; EUROSCARF, Frankfurt, Ger-
many) was used to construct the yeasts secreting GLP1R 
agonists, including GLP1, S2-GLP1 substituted with 
serine at the position 2 of GLP1, and exendin-4 (Ex4), 
a naturally occurring peptide found in the saliva of the 
Gila monster (Furman 2012). Yeast transformants were 
selected on synthetic dextrose (SDC) solid medium 
[0.67% (w/v) yeast nitrogen base without amino acids, 
2% (w/v) glucose, 1% (w/v) casamino acids, 0.002% (w/v) 
adenine, 0.002% (w/v) l-tryptophan, and 2% (w/v) agar], 
and then, the resultant colonies were cultivated in 6-well 
plate (353046; Thermo Fisher Scientific, Waltham, MA, 
USA) or 96-well plate (353072; Thermo Fisher Scientific) 
containing a liquid SDC medium or Dulbecco’s modified 
Eagle Medium (DMEM) (Nacalai Tesque, Kyoto, Japan) 
at 30°C.
Chinese hamster ovary (CHO) cells (85050302; Euro-
pean Collection of Cell Cultures, Salisbury, UK) were 
used as a host cell stably producing human GLP1R and 
cultivated in Ham-F12 (Sigma-Aldrich, St. Louis, MO, 
USA) containing 10% FBS (Thermo Fisher Scientific) and 
400 μg/mL G418 (Nacalai Tesque).
Construction of peptide‑secreting yeast
All the primers used in plasmid construction are listed 
in Table 1. For peptide secretion in yeast, pULS harbor-
ing the engineered secretion signal of yeast α-factor, 
appS4 (Rakestraw et  al. 2009), in the downstream 
of GAPDH promoter, was constructed as follows. 
The DNA fragment encoding the appS4 (FASMAC, 
Kanagawa, Japan) in pUC19 was amplified using prim-
ers 1 and 2, and was inserted into pULI1 (Miura et  al. 
2012), which was digested with EcoRI and XbaI by 
using In-Fusion (Clontech Laboratories, Inc., Mountain 
View, CA, USA) to obtain pULS. The DNA fragments 
encoding GLP1, S2-GLP1 and Ex4, with or without 
a FLAG-encoding sequence at the 3′ terminus, were 
double-stranded from oligonucleotides with the mutual 
complementary region using DNA polymerase KOD-
FX-Neo (Toyobo). The double-stranded DNAs encoding 
those GLP1 analogues were introduced into the multi-
ple cloning sites of pULS by In-Fusion (Clontech) and 
named pULS-GLP1, -GLP1FLAG, -S2-GLP1, -S2-GLP-
1FLAG, -Ex4 and -Ex4FLAG, respectively. Yeasts were 
transformed with those plasmids using Frozen-EZ Yeast 
Transformation-II kit (Zymo Research, Orange, CA, 
USA), resulting in GLP1-yeast, GLP1F-yeast, S2-GLP1-
yeast, S2-GLP1F-yeast, Ex4-yeast, and Ex4F-yeast, 
Table 1 Primers used in this study
Underlines indicate homologous region to the corresponding plasmids.
Sequence
Primer 1 5′-AAACACACATAAACACCCGGGATG-3′
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respectively. Yeast transformed with pULS (Ctrl-yeast) 
was used as control.
Construction of human GLP1R‑producing CHO
Human GLP1R gene was PCR-amplified from the human 
brain cDNA library (BioChain, Newark, CA, USA) using 
DNA polymerase KOD-Plus-Neo (Toyobo) with prim-
ers 3 and 4 (Table 1). The DNA fragment coding human 
GLP1R was inserted into pIRES (Clontech) digested 
with EcoRV and BamHI by using In-Fusion (Clontech), 
resulting in pIRES-hGLP1R. CHO cells were transfected 
with pIRES-hGLP1R using Xfect (Clontech), and then, 
selected with G418 for about 2 weeks to construct a sta-
ble cell line producing hGLP1R. Single cell cloning of the 
resistant cells was conducted by limiting dilution, result-
ing in GLP1R-CHO.
GLP1R activation assay using GLP1R‑CHO
GLP1R-CHO was seeded onto a 96-well plate at 5 × 104 
cells and cultured at 37°C for 24  h. After the cells were 
washed with HANKS buffer (Thermo Fisher Scien-
tific), synthetic GLP1R agonists (GLP1 and Ex4; Peptide 
Institute, Osaka, Japan. S2-GLP1; Bachem, Bubendorf, 
Switzerland) or culture supernatants of GLP1R agonists-
secreting yeast were added and incubated at 37°C for 
45 min. Then, the cells were lysed with Assay/Lysis buffer 
(Thermo Fisher Scientific) and the level of cyclic AMP in 
the cell lysate was determined by using the cAMP-screen® 
assay (Thermo Fisher Scientific) according to the manu-
facturer’s instructions.
Model screening of Ex4‑secreting yeast
Ten yeast cells comprised of Ctrl-yeast and Ex4-yeast 
in the theoretical ratio of 9:1 were seeded into 16 wells 
in 96-well plate containing 300 µL of SDC medium and 
grown for 48  h. Then, the medium was exchanged into 
250 µL of DMEM and yeasts were additionally cultivated 
for 12 h at 30°C. After that, the supernatant was subjected 
to the GLP1R activation assay mentioned above. Yeasts 
included in three wells showing or not showing activity 
were seeded on SDC solid medium to form single colo-
nies. Then, 48 colonies were subjected to colony-direct 
PCR with primers 5 and 6 (Table  1), and the resultant 
PCR products were analyzed by agarose gel electropho-
resis to identify yeasts with the Ex4 gene.
Results
Construction of stable CHO cells producing human GLP1R
CHO cells producing human GLP1R (GLP1R-CHO) were 
constructed to detect functional activity of synthetic- or 
yeast-secreted GLP1R agonists. CHO cells were trans-
fected with pIRES-hGLP1R by lipofection and selected 
using the neomycin resistance gene on the pIRES vector. 
The established  cells showed cAMP production upon 
GLP1R activation by three kinds of synthetic GLP1R ago-
nists, GLP1, S2-GLP1, and Ex4 in a dose-dependent man-
ner, with EC50 value of 5.8, 21.5 and 1.4 nM, respectively 
(Figure 1; Table 2). Therefore, functional human GLP1R 
was successfully produced in CHO cells.
Medium optimization for GLP1R activation 
by yeast‑secreted peptides and establishment  
of assay system
We first tested which medium was suitable for yeast 
growth and evaluation of GLP1R activation in GLP1R-
CHO in 6-well plates. Ctrl-yeast and Ex4-yeast were 
inoculated in a 6-well plate containing SDC medium 
or DMEM at the initial optical density (OD) which was 
600  nm of 0.1 and incubated for 40  h. Then, the growth 
rates of yeasts and the GLP1R activation in GLP1R-CHO 
by culture supernatant containing yeast-secreted peptides 
were evaluated (Figure 2). As a result, SDC gave a higher 
growth reaching stationary phase at 20 h, showing about 
90-fold expansion. On the other hand, yeasts cultivated 
Table 2 Amino acid sequences of GLP1R agonists used in 
this study
Underlines indicate amino acids different from GLP1.


























Figure 1 Dose–response curve of GLP1R activation in GLP1R-CHO 
upon treatment of synthetic GLP1R agonists. GLP1R-CHO cells were 
exposed to three kinds of GLP1R agonists, GLP1 (white circle), S2-GLP1 
(black square) and Ex4 (black diamond), at increasing concentrations. 
After 45 min incubation, cells were lysed and cAMP production was 
determined by ELISA as indicated in “Materials and methods”.
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in DMEM showed much lower growth, reaching only the 
maximal OD600 of 0.75 at 20  h (Figure 2a). For GLP1R 
activation potency after the 40-h cultivation, the culture 
supernatant of Ex4-yeast grown in SDC showed no activ-
ity, although exogenously added Ex4 activated GLP1R by 
16-fold, compared with the control. In contrast, Ex4-yeast 
grown in DMEM strongly induced GLP1R activation 
by 50-fold compared to the Ctrl-yeast (Figure 2b). These 
results indicate that SDC medium is suitable for yeast pro-
liferation, while DMEM is excellent for GLP1R activation.
Next, we tried to establish a GLP1R activation assay 
system combined with peptide-secreting yeast in a 
96-well plate format. We first determined the number 
of Ex4-yeasts required for larger dynamic range in the 
GLP1R activation. Yeast cells suspended in DMEM were 
prepared at 4  ×  104 to 5  ×  106 cells in 96-well plates, 
and after a 12  h-cultivation at 30°C, a GLP1R activa-
tion assay using the culture supernatants was carried 
out (Figure  3a). The results showed that 4  ×  104 yeast 
cells were enough to detect GLP1R activation, show-
ing 73-fold activation, compared with the control, and 
1 ×  106 yeast cells provided the largest dynamic range 
with 224-fold activation of GLP1R. Further, we inves-
tigated the cultivation time required for the yeast cell 
number of 1 × 106 (Figure 3b). Yeast preparations with 
the initial cell number of 3 were cultivated in SDC 
medium that showed the highest growth as in Figure 1, 
and then, yeast cell number was counted at 24, 48, and 
72  h cultivation. As results, the cell number per initial 
cell number exceeded 1 × 106 cells after 48 h cultivation. 
These results suggested that a single yeast cell can reach 
1  ×  106 cells, showing the highest dynamic range in 
GLP1R activation assay when cultivated in SDC for 48 h.
Direct functional assay of various yeast‑secreted GLP1R 
peptide agonists
Based on these optimizations, we constructed a series 
of workflow for direct functional assay of yeast-secreted 
peptides on GLP1R, composed of three steps (Figure 4a): 
cultivation for yeast growth, peptide secretion in yeasts, 
and GLP1R activation assay using GLP1R-CHO. To 
demonstrate the effectiveness of the direct functional 
assay system, we attempted to detect the GLP1R acti-
vation by native GLP1, its analogue S2-GLP1, and Ex4 
secreted by yeast. Single colonies of the yeasts secret-
ing GLP1, S2-GLP1, and Ex4 were inoculated and incu-
bated in a 96-well plate containing SDC for 48  h, and 
then, the medium was exchanged into DMEM with 
additional incubation of 12  h, followed by the GLP1R 




































































Figure 2 Medium optimization for GLP1R activation assay of yeast-secreted peptides. Yeasts were grown in SDC and DMEM on 6-well plate for 
40 h, and then, growth rate (a) and GLP1R activation potential of their culture supernatant (b) were evaluated by measurement of absorbance at 
600 nm and ELISA for cAMP, respectively. For growth curve, white circle indicates Ctrl-yeast and black diamond shows Ex4-yeast. The data represent 
the average ± SEM of three independent experiments.
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showed the highest activation by 59-fold, GLP1 and S2-
GLP1 secreted by yeasts provided only 5.8 and 1.7-fold 
activation, respectively. Therefore, GLP1 and S2-GLP1 
were considered insufficient given those EC50 values are 
a quarter and one sixteenth of the Ex4 values, respec-
tively. Whereas the N-terminal two residues (His-Ala) in 
GLP1 are reported to be critical for its biological activ-
ity, the C-terminal part is tolerable to various modifica-
tions such as fatty acid conjugation or albumin fusion 
(Baggio et al. 2004; Madsen et al. 2007). Thus, we fused 
FLAG tag to the C-terminus of GLP1, S2-GLP1, and Ex4 
initially for affinity purification and Western blotting, if 
needed. Remarkably, when we evaluated the GLP1R acti-
vation potency for such yeast-secreted GLP1R agonists 
with the FLAG tag, GLP1 and S2-GLP1 activated GLP1R 
about 10-times higher than those without the FLAG 
tag, respectively. These results demonstrated that yeast-
secreted GLP1 and S2-GLP1 with the addition of C-ter-
minal FLAG tag were successfully and directly detected 
without any purification and condensation by using the 
novel functional detection system established here.
Examination of model screening using our established 
functional assay system
Finally, we performed a model screening of yeast by 
applying the direct functional assay system, for exam-
ple, a screening of Ex4-yeast in the co-presence of excess 
Ctrl-yeast. A yeast cell mixture including Ctrl-yeast and 






























Number of yeast cells Cultivation time
Figure 3 Scale-down assay for GLP1R activation by yeast-secreted peptides. a Indicated number of yeast cells, Ctrl-yeast (left bar) or Ex4-yeast 
(right bar), were seeded in a 96-well plate containing DMEM and incubated for 12 h. Then, GLP1R activation assay was conducted to find the yeast 
cell number providing wider dynamic range. The data represent the average ± SEM of three independent experiments. b Yeast cultivation time to 
achieve the target yeast cell number, 1 × 106, was evaluated. Yeasts were seeded in a 96-well plate containing SDC at the initial number of 3. After 
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Figure 4 Direct activity detection of various yeast-secreted GLP1R agonists. a Schematic illustration for direct activity detection assay was depicted. 
Single colony of yeasts was inoculated in 96-well plate containing SDC and cultivated for 48 h. After removal of SDC, DMEM was added and 
incubated for additional 12 h. Then, the culture was subjected to GLP1R activation assay using GLP1R-CHO. b Seven kinds of yeasts were tested for 
GLP1R activation potency according to the assay flow mentioned above. The data represent the average ± SEM of three independent experiments.
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Ex4-yeast at a theoretical ratio of 9:1 was prepared, and a 
GLP1R activation assay was conducted according to the 
determined workflow (Figure 5a). As a result, we identi-
fied three positive wells showing GLP1R activation (Fig-
ure 5b). We next investigated the existence of Ex4-yeast 
in the positive and negative wells by colony-direct PCR 
after the colony formation of yeasts from both wells. The 
results indicated the existence of 24% of Ex4-yeast in the 
positive wells, whereas Ex4-yeast was not identified at all 
in the negative wells (Figure 5c). These results clearly sug-
gest that our direct functional assay system established 
was effective in the model screening.
Discussion
In this study, we established the novel functional screen-
ing system of yeast-secreted peptides acting on GLP1R. 
The system directly detected the functional activity of 
yeast secreted-GLP1R agonists based on activation of 
GLP1R produced on mammalian cells, without any puri-
fication and condensation of yeast-produced peptides. In 
addition, application of the system enabled identification 
of agonist-secreting yeast in the model screening.
Binding-based peptide screening strategy as repre-
sented by phage display has been the most common 
method used to discover novel peptide-ligands for 
certain drug targets, including GPCRs (Molek et al. 2011; 
Vyroubalova et al. 2006). However, with peptides discov-
ered through this methodology, it is uncertain whether 
they are biologically active or not. In addition, phage-dis-
played peptides are distinct from functional peptides in 
their soluble form. These conventional challenges result 
in additional chemical synthesis of the identified peptides 
in soluble form to evaluate their true biological activity, 
which are time-consuming and quite expensive.
In the first optimization step using Ex4-yeasts as a 
model for our novel functional assay system, we remark-
ably found that DMEM buffered at neutral pH designed 
for mammalian cell culture was very suitable for yeast 
peptide secretion and GLP1R activation in mamma-
lian cells, even though yeast cells could not grow in the 
medium. Another remarkable point in this culture sys-
tem is a protection of the target peptides from degrada-
tion by yeast-derived proteases. Because heterologous 
proteins produced in yeasts could be degraded during 
several steps, including the intracellular secretory path-
ways and the post-secreted extracellular environment 
(Idiris et al. 2010), yeast-derived proteases such as Yps1p 
and Kex2p, which are most active at a mild acidic con-
dition around pH 5.0, are considered accessible to heter-
ologous proteins, especially when yeasts are incubated in 
9:1 yeast mixture
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Colonies from the positive well
Colonies from the negative well
Figure 5 Model screening of Ex4-secreting yeast using the direct activity detection system. a Schematic illustration for model screening of 
Ex4-yeast was indicated. b We prepared 16 wells including 9:1 yeast mixture (10 cells in total per well) in the ratio of Ctrl-yeast to Ex4-yeast and con-
ducted GLP1R activation assay according to the workflow indicated above. Only Ctrl-yeast or Ex4-yeast was tested as a control. c The existence of 
Ex4-yeast in the positive and negative wells was investigated by colony-direct PCR after the colony formation of yeasts from both wells (numbering 
from 1 to 24 means the number of colony picked up). The representative electrophoresis data are shown for colonies from a positive and a negative 
well, respectively. M molecular size marker (New England Biolabs, Ipswich, MA, USA).
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SDC medium, which generally has pH 4.5–5.5 (Mizuno 
et al. 1989; Olsen et al. 1999). In addition, yeasts were a 
good tool for producing peptides because yeasts swiftly 
grew in SDC medium; they even in a static 96-well plate 
setting which would be compatible with high-throughput 
screening and could easily reach the targeted yeast cell 
number providing high dynamic range in GLP1R activa-
tion assay (Figure 2).
These findings prompted us to conduct the direct func-
tional detection of other GLP1R agonists with weaker 
activity than Ex4, GLP1, and S2-GLP1 to be secreted by 
yeasts. It was difficult to detect their GLP1R activation 
potency at the high level as expected from the difference 
of the EC50 value of Ex4. Surprisingly, the C-terminus 
fusion of the FLAG tag with DYKDDDDK in GLP1 and 
S2-GLP1 much increased the GLP1R activation potency 
by about tenfold compared to those without the FLAG 
tag (Figure 4b). In spite of the fact that the precise mech-
anisms of the FLAG are still uncertain, the beneficial 
effect of the FLAG fusion was also observed in somato-
statin that is endogenous circular peptide agonist acting 
on class A GPCR SST receptor (data not shown). Accord-
ingly, the FLAG fusion to isolated peptides would be a 
promising way to increase their activity.
As shown in Figure  5, we successfully identified the 
wells including Ex4-yeast by evaluating the GLP1R acti-
vation potency, and importantly, the wells that did not 
show activity did not possess any Ex4-yeast, as confirmed 
by colony-direct PCR detecting Ex4 gene. This success-
ful model screening of yeasts secreting agonists acting 
on GLP1R encourages us to carry out an actual screening 
for novel bioactive peptides through our direct functional 
detection system.
In conclusion, we successfully established a novel sys-
tem for direct functional assay for yeast-secreted pep-
tides on GLP1R. This system will be applied not only for 
biological activity assay of sequenced peptides instead of 
their chemical synthesis but also discovery of novel bio-
active peptides.
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